NCT04292119 - Lorlatinib Combinations in Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

March 1, 2023

Conditions

Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 RearrangementRelapsed CancerMET AmplificationResistant CancerNSCLC

Interventions

DRUG

Lorlatinib

"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."

DRUG

Crizotinib

"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."

DRUG

Binimetinib

Binimetinib will be taken orally twice daily for 28 days.

DRUG

TNO155

TNO155 will be taken orally once daily for 14 days.

Trial Locations (2)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston